
QA Specialist

è·ä½æè¿°
Job Purpose工作目的
1. The role is responsible for batch document reviewed timely, perform QA oversight in PU, and assure that Products’ production activity complies with Novartis Quality Policy and GMP requirement.
è² è²¬æ‰¹æ–‡ä»¶çš„åŠæ™‚å¯©æ ¸ï¼Œå¯¦æ–½ç¾å ´æª¢æŸ¥ï¼Œå¹¶ç¢ºä¿ç”Ÿç”¢éŽç¨‹ç¬¦åˆè«¾è¯è³ªé‡æ‰‹å†Šå’ŒGMPè¦æ±‚。
Major Accountabilities 主è¦è·è²¬
Principal Job Objectives 主è¦å·¥ä½œç›®æ¨™
1. Review Batch Document and records timely and ensure that the following requirements have been met:
åŠæ™‚å¯©æ ¸æ‰¹æ–‡ä»¶å’Œè¨˜éŒ„å¹¶ç¢ºä¿æ»¿è¶³ä»¥ä¸‹è¦æ±‚:
1) All the necessary checks and tests have been performed. ç¢ºä¿æ‰€æœ‰å¿…è¦çš„æª¢æŸ¥å’Œæ¸¬è©¦å·²ç¶“實施。
2) Review QC testing record and confirm that QC report had been approved by coordinators trained in appropriate disciplines and the product quality conforms to specifications.
å¯©æ ¸QC檢測記錄并確èªQCå ±å‘Šå·²ç¶“ç”±åŸ¹è¨“éŽçš„å”調員批準并確èªç”Ÿç”¢çš„產å“符åˆè¦å®šçš„è³ªé‡æ¨™æº–。
3) All necessary production documentation has been completed and endorsed by coordinators trained in appropriate disciplines and confirm that batch manufacturing activities are in compliance with Novartis quality policy, local regulatory and GMP requirements.
所有必è¦çš„生產文件已完æˆä¸”已經由培訓éŽçš„å”èª¿å“¡æ ¸æº–éŽ, 并確èªç”Ÿç”¢éŽç¨‹ç¬¦åˆè«¾è¯è³ªé‡æ‰‹å†Šã€æœ¬åœ°æ³•è¦å’ŒGMPè¦æ±‚ï¼›
4) The marketing authorization and the manufacturing authorization requirements for the product have been met for the batch concerned; ç¢ºä¿æ‰¹æ¬¡ç”¢å“符åˆå¸‚å ´æº–å…¥è¦æ±‚和生產åˆè¦è¦æ±‚ï¼›
5) The principles and guidelines of GMP, as laid down in the guidelines published by HA, have been followed; 確ä¿éµå¾ªè¡›ç”Ÿç®¡ç†éƒ¨é–€é ’布的GMP原則和指導方é‡ï¼›
6) The principal manufacturing and testing processes have been validated, if different; é—œéµç”Ÿç”¢å·¥è—和檢驗方法變更時è¦ç¶“éŽé©—è‰ï¼›
7) Any changes or deviations in manufacturing or quality control have been notified and evaluated in accordance with a well-defined system before any product is released; åœ¨ç”¢å“æ”¾è¡Œå‰ï¼Œä»»ä½•ç”Ÿç”¢æˆ–è³ªé‡æŽ§åˆ¶ä¸è®Šæ›´å’Œå差需è¦é€šéŽå¥å…¨çš„ç³»çµ±ä¾†é€²è¡ŒåŒ¯å ±å’Œè©•ä¼°ï¼›
8) All relevant factors have been considered, including any not specifically associated with the output batch directly under review (e.g. subdivision of output batches from a common input, factors associated with continuous production runs). å¯©æ ¸æ‰¹æ–‡ä»¶è¦è€ƒæ…®æ‰€æœ‰ç›¸é—œå› ç´ ï¼ŒåŒ…æ‹¬èˆ‡ç”¢å“æ²’有明確關è¯çš„å› ç´ ï¼ˆä¾‹å¦‚æ£å¸¸æ‰¹æ¬¡çš„åˆ†æ‰¹ï¼Œé€£çºŒç”Ÿç”¢æ‰¹æ¬¡çš„å½±éŸ¿å› ç´ ï¼‰ã€‚
2. Master document updated
主文件的更新
Review master document (E.g.: MBD, MCR and MBR, etc.) timely, and assure that master document complies with requirement of validation protocol, registration file, etc.
åŠæ™‚å¯©æ ¸ä¸»æ–‡ä»¶ï¼ˆä¾‹å¦‚ï¼šä¸»æ–‡ä»¶ï¼Œä¸»æ¸…æ½”è¨˜éŒ„å’Œä¸»æ‰¹å ±ç‰ï¼‰ï¼Œç¢ºä¿ä¸»æ–‡ä»¶ç¬¦åˆé©—è‰æ–¹æ¡ˆå’Œæ³¨å†Šæ–‡ä»¶ç‰ç›¸é—œçš„è¦æ±‚。
3. Document archived:
æ–‡ä»¶å˜æª”:
Safely archive relevant Documentation(e.g.: Batch Document, Cleaning Record, Master Batch Document, Master Cleaning Record, etc.)for the prescribed date.
確ä¿è³ªé‡ç›¸é—œæ–‡ä»¶(例如:批記錄,清潔記錄,主批文件,主清潔記錄ç‰)安全地在è¦å®šæ™‚é–“å…§å‡è¢«å˜æª”。
4. QA Oversight:
QA 監管:
GMP monitoring, perform the oversight review as shift QA, escalate timely and push correction or follow up related corrective action.
生產GMPç¾å ´ç›£æŽ§ï¼Œä½œç‚ºå€’çQA執行生產ç¾å ´æª¢æŸ¥ï¼Œå¹¶åŠæ™‚åŒ¯å ±ï¼ŒæŽ¨å‹•å’Œè·Ÿè¹¤ç›¸æ‡‰çš„æ•´æ”¹æ´»å‹•ã€‚
5. Training:
培訓:
Complete individual training according to Individual Annual Training Plan, and other training.
æ ¹æ“šå€‹äººå¹´åº¦åŸ¹è¨“è¨ˆåŠƒå®Œæˆå€‹äººåŸ¹è¨“和其它培訓。
6. Oversee the execution of in-process control
監ç£ä¸é–“控制的執行和評估
1) Understands the related products efficacy, property and test points which should be paid special attention.
Understands information of product quality reflected from test results.
了解å„產å“ç‰¹æ€§åŠæ¸¬è©¦é—œæ³¨é»žï¼Œç†è§£ä¸é–“控制å„é …æ¸¬è©¦çš„åŽŸç†å’Œç›®çš„。ç†è§£æ¸¬è©¦çµæžœæ‰€åæ˜ çš„ç”¢å“質é‡ä¿¡æ¯ã€‚
2) Review relavant logbook used in IPC.
å¯©æ ¸ä¸é–“控制éŽç¨‹ç›¸é—œæ—¥å¿—。
3) Monitor the operation of in-process control complies with approved test method.
監控ä¸é–“控制æ“作éŽç¨‹ç¬¦åˆæ‰¹æº–çš„æ–¹æ³•è¦æ±‚。
7. Other:
其他:
1) Complete CAPA timely which triggered from deviation, internal audit or other external audit.
åŠæ™‚完æˆç”±å差,內部審計或其它審計產生的整改措施。
2) Perform change request releted evaluation.
執行變更相關的評估。
3) Provide effective compliance supporting and services to others.
為其他部門æä¾›åˆè¦æ–¹é¢çš„æœ‰æ•ˆæ”¯æŒå’Œæœå‹™ã€‚
4) Assist QA investigation for noncompliance. å”助 QA進行ä¸åˆè¦æ–¹é¢çš„調查 。
5) Give basic training for PU employees as the purpose of RFT of batch document improvement. æä¾›åŸºç¤ŽåŸ¹è¨“,以æé«˜PUæ“ä½œäººå“¡æ‰¹æ–‡ä»¶ä¸€æ¬¡åˆæ ¼çŽ‡ã€‚
6) Attend to any other work related assignment, which may be given by the superior. 完æˆä¸Šç´šæŒ‡å®šçš„其他工作。
7) Monitor effectiveness of quality systems within the PU.監ç£é‹ç‡Ÿéƒ¨é–€è³ªé‡é«”系的有效性。
Key Performance Indicators ç¸¾æ•ˆè€ƒæ ¸æŒ‡æ¨™
1. Review batch documents and cleaning record and ensure quality of BD/CR. å¯©æ ¸æ‰¹æ–‡ä»¶åŠæ¸…潔記錄,ä¿è‰æ‰¹æ–‡ä»¶åŠæ¸…潔文件的質é‡ã€‚
2. Review MBD/MBR/MCR and ensure quality of MBD/MBR/MCR. 審閱主批文件\ä¸»æ‰¹å ±\主清潔記錄,ä¿è‰ä¸»æ‰¹æ–‡ä»¶\ä¸»æ‰¹å ±\主清潔記錄的質é‡ã€‚
3. Perform QA oversight following project time line and push correction or follow up related corrective action. 按計劃å°ç”Ÿç”¢éŽç¨‹é€²è¡Œç›£ç£ï¼ŒæŽ¨å‹•和跟蹤相應的整改活動。
4. Support audit when necessary and ensure no critical or major finding during audit. åœ¨å¯©è¨ˆä¸æä¾›å¿…è¦çš„æ”¯æŒï¼Œ å¹¶ä¸”ç¢ºä¿æ²’æœ‰åš´é‡æˆ–主è¦ç™¼ç¾é …。
Ideal Background ç†æƒ³çš„背景
Education:教育
Bachelor degree above本科åŠä»¥ä¸Šå¸æ·
Languages:語言
Fluent in spoken, written, listening and reading English and Chineseä¸ã€è‹±æ–‡è½ã€èªªã€è®€ã€å¯«ç†Ÿç·´
Experience:工作經驗
2 years’ experience in Pharmaceutical Industry2å¹´ä»¥ä¸Šè—¥å» å·¥ä½œç¶“é©—
伿¥ç°¡ä»‹
諾è¯å…¬å¸
諾è¯å…¬å¸ï¼ˆNYSE: NVS)總部ä½äºŽç‘žå£«å·´å¡žçˆ¾ï¼Œæ¥å‹™éåŠå…¨çƒ140多個國家和地å€ï¼Œæ“有96,700ä½å…¨è·å“¡å·¥ã€‚å…¬å¸ç‚ºæ‚£è€…和社會æä¾›é†«è—¥ä¿å¥è§£æ±ºæ–¹æ¡ˆï¼Œä»¥æ»¿è¶³å…¶æ—¥ç›Šè®ŠåŒ–的需求。諾è¯å°ˆæ³¨äºŽé†«è—¥ä¿å¥çš„å¢žé•·é ˜åŸŸï¼Œæ“æœ‰å‰µæ–°è—¥å“ã€æˆæœ¬ç¯€ç´„åž‹éžå°ˆåˆ©è—¥å“ã€é 防性疫苗åŠè¨ºæ–·è©¦åŠ‘ï¼Œä»¥åŠæ¶ˆè²»è€…ä¿å¥ç”¢å“ç‰å¤šå…ƒåŒ–çš„æ¥å‹™çµ„åˆï¼Œä»¥æ¤æœ€å¥½åœ°æ»¿è¶³æ‚£è€…å’Œç¤¾æœƒçš„éœ€æ±‚ã€‚è«¾è¯æ˜¯å”¯ä¸€åœ¨ä¸Šè¿°å››å¤§é ˜åŸŸå‡è™•äºŽé ˜å…ˆä½ç½®çš„å…¬å¸ã€‚諾è¯é›†åœ˜2008 年實ç¾å‡ˆéŠ·å”®é¡å¢žé•· 9%(以當地貨幣計為 5%),é”415億美元,經營收入增長 32%,é”90億美元。全çƒèŒƒåœå…§ï¼Œåˆ¶è—¥ï¼ˆå°ˆåˆ©è—¥ï¼‰æ¥å‹™å¢žé•·å‹¢é å¼·å‹ï¼Œç–«è‹—åŠè¨ºæ–·è©¦åŠ‘ä»¥åŠæ¶ˆè²»è€…ä¿å¥å“æ¥å‹™ä¹Ÿæœ‰è‰¯å¥½è¡¨ç¾ã€‚
è«¾è¯æºäºŽæ‹‰ä¸æ–‡novae artes,æ„為“新技術â€ã€‚å…¬å¸çš„䏿–‡åå———諾è¯ï¼Œå–æ„æ‰¿è«¾ä¸è¯ï¼Œå³æ‰¿è«¾é€šéŽä¸æ–·å‰µæ–°çš„產å“å’Œæœå‹™è‡´åŠ›äºŽæé«˜ä¸åœ‹äººæ°‘çš„å¥åº·æ°´å¹³å’Œç”Ÿæ´»è³ªé‡ã€‚諾è¯åœ¨ä¸åœ‹æœ‰ä¸ƒå®¶ä¼æ¥å’Œä¸€å®¶ç¶œåˆç ”發ä¸å¿ƒï¼Œåˆ†åˆ¥æ˜¯åŒ—京諾è¯åˆ¶è—¥æœ‰é™å…¬å¸ã€è˜‡å·žè«¾è¯åˆ¶è—¥ç§‘技有é™å…¬å¸ã€å±±å¾·å£«(ä¸åœ‹)制藥有é™å…¬å¸åŠå±±å¾·å£«è²¿æ˜“有é™å…¬å¸, 上海諾è¯è²¿æ˜“有é™å…¬å¸, 上海視康貿易有é™å…¬å¸,上海諾è¯å‹•物ä¿å¥æœ‰é™å…¬å¸, 諾è¯(ä¸åœ‹)生物醫å¸ç ”究有é™å…¬å¸ï¼Œç¸½æŠ•資超éŽ3.3億美元。目å‰è«¾è¯åœ¨ä¸åœ‹é›‡å“¡è¶…éŽ3,500人,2008年總銷售é¡è¶…éŽ33億元人民幣,比2007年增長29%。
作為公å¸çš„價值觀,諾è¯åœ¨æ·ç¶“250年的發展éŽç¨‹ä¸ï¼Œåœ¨å¯¦ç¾æ¥å‹™å¢žé•·çš„åŒæ™‚,也為患者和員工æä¾›é—œæ„›ã€‚ç›®å‰ï¼Œç›¡ç®¡å…¨çƒç¶“濟æ£é¢è‡¨è¡°é€€çš„壓力, 諾è¯ä»å°‡æœƒç¹¼çºŒåŠ å¤§åœ¨è¯æŠ•è³‡åŠ›åº¦, 支æŒåœ¨è¯æ¥å‹™å¯æŒçºŒçš„增長和擴展。在人æ‰åŸ¹é¤Šæ–¹é¢ä¹Ÿé€²ä¸€æ¥åŠ å¤§æŠ•å…¥ï¼Œå°‡æˆç«‹è«¾è¯ä¸åœ‹å¤§å¸ã€‚åŒæ™‚,諾è¯å°‡åœ¨ä¸åœ‹å‰µé€ æ›´å¤šå°±æ¥æ©Ÿæœƒï¼Œé‚€è«‹æ›´å¤šäººæ‰åР入公å¸ï¼Œå“¡å·¥ç¸½æ•¸å°‡æœƒå¯¦ç¾20%增長。這表明諾è¯å°ä¸åœ‹å¸‚å ´çš„ä¿¡å¿ƒï¼Œæ›´æ˜¯å°â€œæ‰¿è«¾ä¸è¯â€çš„æ›´å¥½å¯¦è¸ã€‚
北京諾è¯åˆ¶è—¥æœ‰é™å…¬å¸
1996å¹´,繼瑞士汽巴-嘉基公å¸å’Œå±±å¾·å£«å…¬å¸å…¨çƒå®Œæˆåˆå¹¶ä¹‹åŽ,其在è¯åˆ¶è—¥æ¥å‹™å¯¦æ–½åˆå¹¶,æˆç«‹äº†è«¾è¯åœ¨ä¸åœ‹çš„第一家公å¸â€”—北京諾è¯åˆ¶è—¥æœ‰é™å…¬å¸ã€‚
å幾年來,北京諾è¯åˆ¶è—¥å–得了驕人的æ¥ç¸¾,æ¥å‹™éåŠå…¨åœ‹260多個城市。在éŽåŽ»ä¸ƒå¹´é‡Œ,北京諾è¯åˆ¶è—¥å¹³å‡å¢žé•·é€Ÿåº¦è¶…éŽ20%,æˆç‚ºè«¾è¯é›†åœ˜ä¸å¢žé•·æœ€é«˜çš„å…¬å¸ä¹‹ä¸€ã€‚北京諾è¯åˆ¶è—¥2008年銷售增長超éŽ30%,åœ¨è·¨åœ‹é†«è—¥ä¼æ¥ä¸æŽ’å第三。
諾è¯åˆ¶è—¥åœ¨ä¸åœ‹è¨ç«‹å¸¸ç”¨è—¥å“事æ¥éƒ¨ã€æŠ—感染藥å“事æ¥éƒ¨ã€ç§»æ¤åŠä¸æ¨žç¥žç¶“è—¥å“事æ¥éƒ¨ã€çœ¼ç§‘è—¥å“事æ¥éƒ¨å’Œè…«ç˜¤è—¥å“事æ¥éƒ¨,實施å€åŸŸåŒ–管ç†,建立了極具競çˆåŠ›çš„ç”¢å“組åˆã€‚å…¬å¸åœ¨å¿ƒè¡€ç®¡ã€å…§åˆ†æ³Œã€æŠ—感染ã€è…«ç˜¤ã€ç§»æ¤å…ç–«ã€é¢¨æ¿•疼痛ã€éª¨ä»£è¬ã€çœ¼ç§‘ã€ä¸æ¨žç¥žç¶“系統ç‰9å¤§é ˜åŸŸæ“æœ‰30多種國際一æµçš„高科技專利產å“。
抗高血壓藥å“代文?æˆç‚ºä¸åœ‹è¡€ç®¡ç·Šå¼µç´ IIå—體拮抗劑(ARB)é ˜åŸŸå¸‚å ´ä»½é¡ç¬¬ä¸€çš„å“牌,å¦ä¸€ç¶“典抗高血壓藥物洛汀新?ä¹Ÿç¹¼çºŒä¿æŒåŒé¡žè—¥å“å¸‚å ´ä»½é¡ç¬¬ä¸€,洛汀新?和代文?兩種產å“2008年銷售é¡ç¸½è¨ˆçªç ´10億人民幣。公å¸å¦ä¸€ç¨®æ…¢æ€§ä¹™è‚æ²»ç™‚è—¥ç‰©ç´ æ¯”ä¼?自2007年上市以來,僅用兩年時間å³ååˆ—å¸‚å ´å æœ‰çŽ‡ç¬¬3ä½ã€‚諾è¯åˆ¶è—¥é‚„ç©æ¥µæŽ¨é€²åˆè¦æ–‡åŒ–,致力æˆç‚ºå±¥è¡Œè¡Œæ¥è¦èŒƒçš„é ˜å…ˆè€…,æˆç‚ºä¸åœ‹æœ€å…·è·æ¥æ“å®ˆçš„è·¨åœ‹é†«è—¥ä¼æ¥ä¹‹ä¸€ã€‚
北京諾è¯åˆ¶è—¥ä¹Ÿéžå¸¸é‡è¦–客戶的需求,致力于æé«˜å®¢æˆ¶æ»¿æ„åº¦ã€‚æ ¹æ“šTNSå¸‚å ´ç ”ç©¶å…¬å¸â€œ2008客戶滿æ„度調查â€,北京諾è¯åˆ¶è—¥é€£çºŒå››å¹´æ¦®è†ºå®¢æˆ¶æ»¿æ„調查榜首。在æ¤åŸºç¤Žä¸Š,2009年北京諾è¯åˆ¶è—¥é€²ä¸€æ¥æŠŠâ€œæ‚£è€…為本â€è¨ç‚ºå…¬å¸æ–‡åŒ–建è¨çš„æ–°é‡é»ž,以為患者æä¾›æœ€å„ªè³ªçš„æœå‹™ç‚ºå®—æ—¨,é€šéŽæŒçºŒå‰µæ–°çš„å„種活動,充分ç†è§£æ‚£è€…ç¶“æ·,解除患者病痛,æé«˜æ‚£è€…的生活質é‡ã€‚
2009å¹´å°äºŽåŒ—京諾è¯åˆ¶è—¥è€Œè¨€æ˜¯â€œéŠ³å‹¢è–„ç™¼â€çš„一年,將有密固é”?(éª¨è³ªç–æ¾)ã€ç±³èŠ™?(ç§»æ¤)ã€Lescol? XL(é™è¡€è„‚)ã€Trileptal? OS(抗癲癇)ã€Exforge?(抗高血壓)å’ŒCibadrex?(抗高血壓)ç‰å…個創新產å“在ä¸åœ‹ä¸Šå¸‚,為廣大患者æä¾›æ›´å¤šæœ‰æ•ˆã€å®‰å…¨çš„è—¥ç‰©é¸æ“‡ã€‚2008年北京諾è¯åˆ¶è—¥é€šéŽå¯¦æ–½â€œåŽšç©â€é …目完善了公å¸çš„å„é …ç®¡ç†åˆ¶åº¦å’Œæµç¨‹,æé«˜äº†é‹ç‡Ÿæ•ˆçŽ‡å’Œæ•´é«”ç«¶çˆåŠ›ã€‚åœ¨æœªä¾†äº”å¹´é‡Œ,通éŽé–‹å±•“薄發â€é …ç›®,北京諾è¯åˆ¶è—¥åŠ›çˆåœ¨æ¥ç¸¾ã€äººæ‰ã€ä¼æ¥ç¾Žè½åº¦ç‰å„æ–¹é¢æˆç‚ºä¸åœ‹é†«è—¥è¡Œæ¥â€œæ¨™æ¡¿ä¼æ¥â€ã€‚
北京諾è¯åˆ¶è—¥æœ‰é™å…¬å¸åˆ¶è—¥å» 是由瑞士ç¨è³‡çš„åˆ¶è—¥å·¥å» ,總投資é¡9000è¬ç¾Žå…ƒã€‚å·¥å» åè½åœ¨åŒ—京市昌平科技園å€,å 地é¢ç©28000平方米,æ“æœ‰ç¾ä»£åŒ–çš„æ½”å‡ˆå» æˆ¿å’Œææ´²å¼•進的全套先進è¨å‚™,劑型主è¦ç‚ºå›ºé«”å’ŒåŠå›ºé«”兩種,年產20億片(è† å›Š)å’Œ1200è¬æ”¯ä¹³è† åŠ‘ã€‚å·¥å» ä½œç‚ºè«¾è¯å…¨çƒæ¨™æº–化GMPå·¥å» ä¹‹ä¸€,統一接å—瑞士諾è¯å…¨çƒåˆ¶è—¥æŠ€è¡“部的技術和質é‡ç®¡ç†ã€‚
è·ä½ç™¼å¸ƒä¼æ¥

北京諾è¯åˆ¶è—¥æœ‰é™å…¬å¸
伿¥æ€§è³ªï¼šåˆè³‡ä¼æ¥
伿¥è¦æ¨¡ï¼š10000人以上
æˆç«‹å¹´ä»½ï¼š1996
伿¥ç¶²å€ï¼šwww.novartis.com.cn
伿¥åœ°å€ï¼šå»ºå¤–大街1號國貿大廈2座13層